



MORE OPTIONS FOR MORE PATIENTS EVOLUT™ TAVI

THE FIRST AND ONLY TAVI PLATFORM CE MARKED for treatment of patients with severe BICUSPID aortic stenosis*

CE ženklinimas išplēstoms indikacijoms – dviburē (bicuspid, - angl.) anatomija



30-DAY OUTCOMES IN BICUSPID VS TRICUSPID¹ WITH EVOLUT™ PLATFORM

Strong clinical and procedure outcomes at 30 days for patients with bicuspid and tricuspid aortic valves.¹

EVOLUT™ TAVI LOW RISK INDICATION

[LEARN MORE](#)